3 Semiconductor Stocks to Trade For Big-Time Gains

3 Semiconductor Stocks to Trade For Big-Time Gains

Stocks go up and stocks go down. But when it comes to the broad and volatile semiconductor sector, variability can even see both happen at the same time. Working to validate that track record are three popular semi stocks indicating investors should be ready to diversify long and short within this important group.It generally remains a smart approach to follow or invest alongside the broader averages. Over longer time frames and during more meaningful market cycles, most listed companies go along, up or down, with the S&P 500 or other broad-based indices. That's common knowledge. It's also why trading with the trend is popular, particularly in rising stock markets like today.In our estimation the current market environment is inviting investors to trade the market long. But as I've recently stressed here at InvestorPlace, trading selectively from the short side is making increasing sense.InvestorPlace - Stock Market News, Stock Advice & Trading...

Death Toll in U.S. at 50,000; Malaria Drug Warning: Virus Update

(Bloomberg) -- The death toll from the new coronavirus reached 50,000 in the U.S., now the epicenter of the global outbreak. The World Health Organization formed an international alliance to ensure that Covid-19 vaccines and treatments are distributed fairly.The U.S. Food and Drug Administration warned patients about taking malaria medications touted by President Donald Trump. The president now claims he was being sarcastic on Thursday when he suggested that injecting disinfectants might ward off the coronavirus.Spain and Italy had their fewest deaths in five weeks, and new cases in Singapore dropped below 1,000 for the first time in five days. Russia reported the most new cases since April 19, and Germany had its worst day in almost a week.Key DevelopmentsVirus Tracker: Cases top 2.7 million; deaths exceed 191,000Pence says outbreak could be over by Memorial DayEurope grapples with lockdowns as cases drop and economies reelMnuchin asks for equity stakes in exchange...

Exclusive: Trial of Gilead's potential coronavirus treatment running ahead of schedule, researcher says

Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy and Infectious Diseases (NIAID), could come even sooner, lead researcher Dr. Andre Kalil told Reuters in an interview. Remdesivir has drawn tremendous attention as a therapy with the potential to alter the course of the disease, based on anecdotal reports that it may have helped some patients....